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The transforming growth factor  (TGF) family has critical roles in the regulation of fertility. In addition,
the pathogenesis of some human cancers is attributed to misregulation of TGF function and SMAD2 or
SMAD4 mutations. There are limited mouse models for the BMP signaling SMADs (BR-SMADs) 1, 5, and 8
because of embryonic lethality and suspected genetic redundancy. Using tissue-specific ablation in mice, we
deleted the BR-SMADs from somatic cells of ovaries and testes. Single conditional knockouts for Smad1 or
Smad5 or mice homozygous null for Smad8 are viable and fertile. Female double Smad1 Smad5 and triple
Smad1 Smad5 Smad8 conditional knockout mice become infertile and develop metastatic granulosa cell tumors.
Male double Smad1 Smad5 conditional knockout mice are fertile but demonstrate metastatic testicular tumor
development. Microarray analysis indicated significant alterations in expression of genes related to the TGF
pathway, as well as genes involved in infertility and extracellular matrix production. These data strongly
implicate the BR-SMADs as part of a critical developmental pathway in ovaries and testis that, when disrupted,
leads to malignant transformation.
The transforming growth factor  (TGF) family regulates
cell proliferation and differentiation in many developmental
and physiological processes, including reproduction (39).
When TGF family function is disrupted, a number of repro-
ductive phenotypes result. These include infertility, germ cell
loss, or, less commonly, tumor formation. For example, genetic
deletion of the inhibin  subunit in mice results in sex cord
stromal tumors and death through a cancer cachexia-like disease
(10, 31). Deletion of follistatin (a negative regulatory protein of
activin) or anti-Mu¨llerian hormone (AMH/MIS) results in pre-
mature ovarian failure (14, 25), and loss of ovarian activin leads to
infertility (37). Less is known about the in vivo contribution of the
BMP subgroup in adult reproductive physiology because muta-
tions in most BMP signaling components result in embryonic
lethality or primordial germ cell loss (7).
The TGF family signals through cell surface serine-threo-
nine kinase receptor complexes that phosphorylate intracellu-
lar SMAD transcription factors (30). TGF, activin, and nodal
receptors signal through SMAD2 or SMAD3 (termed AR-
SMADs), while BMP receptors signal through SMAD1,
SMAD5, or SMAD8 (termed BR-SMADs) (15). Once phos-
phorylated, R-SMADs form complexes with SMAD4 and ac-
tivate or repress target gene transcription in association with a
number of cofactors (30). Loss-of-function mutations in TGF
receptors, SMAD2, or SMAD4 are found in a minority of
cancer types, such as human pancreatic and gastrointestinal
tumors (13, 29). Other cancers exploit the TGF signaling
pathway to promote tissue invasion and metastasis (44). TGF
function is cell type dependent, and the mechanism by which
TGF functions as both a tumor suppressor and an oncogene
in carcinogenesis is unclear (40). Whether signaling by mem-
bers of the BMP subfamily also displays this duality (i.e., loss of
function in some instances and gain of function in others) in
tumor development is unknown.
Some studies have suggested a role for the BMP pathway in
human cancer. Mutations in the BMP type I receptor BMPR1A
are implicated in the pathogenesis of juvenile polyposis syn-
drome and lead to an increase in malignant potential (20, 23).
Mice with tissue-specific inactivation of Bmpr1a also develop
intestinal polyposis (18). Additionally, in vitro, BMPs have
growth-suppressive effects on normal and some cancer cell
lines that have intact BMP signaling components (2, 5, 33, 42),
and the BMP antagonist gremlin has been shown to promote
tumor cell proliferation (50). Recently, the BMP signaling
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pathway was demonstrated to be a key inhibitory regulator of
tumor-initiating cells of human glioblastomas (41). However,
definitive in vivo evidence for a tumor-suppressive role of the
BR-SMAD pathway tissue is lacking (40).
Functional differences between some of the BR-SMADs
have not been established (34). Null mutations in Smad1 or
Smad5 give embryonic lethal phenotypes in mice, but Smad8
homozygous null mice are viable and fertile (1; Z. Huang, D.
Wang, K. Ihida-Stansbury, P. L. Jones, and J. F. Martin, sub-
mitted for publication). Embryonic lethality also occurs in
Smad1/ Smad5/ double heterozygous embryos (1). The
study herein was designed to ablate BR-SMADs in gonadal
somatic cells to examine the function of the BMP pathway in
reproduction. Here we show that Cre-mediated genetic ablation
of either Smad1 or Smad5 in ovarian granulosa cells results in
normal reproductive function but that combined loss of Smad1
and Smad5 results in fertility defects and granulosa cell tumors.
Unlike other mouse models that develop sex cord stromal tumors,
female Smad1 Smad5 double conditional knockout (dKO) mice
develop peritoneal and lymphatic metastases, uncovering a novel
regulatory role in this process for the BR-SMADs. Male Smad1
Smad5 dKO mice also develop metastatic testicular tumors.
These data strongly implicate SMAD1 and SMAD5 as critical
tumor suppressors with redundant functions.
MATERIALS AND METHODS
Mouse strains and breeding. The Smad1 conditional allele (Smad1RobPC)
(designated Smad1flox throughout) and the Smad1 null allele (Smad1Robcn) (des-
ignated Smad1 throughout) have been described elsewhere (53) (Fig. 1A). The
Smad5 null allele (Smad5tm1Zuk) (designated Smad5 throughout) was gener-
ated previously (8). The Smad5 conditional allele (Smad5fle2) (designated
Smad5flox throughout) has been described previously (54). The Smad8 null allele
was generated by deletion of exons 4 and 5, which code for most of the MH2
domain that functions in receptor binding and contains the SSXS phosphoryla-
tion site (Huang et al., submitted). Mice in this study were maintained on a
C57BL/6J;129S5/SvEvBrd mixed hybrid background. For readability, genotypes
are not written in standard order (i.e., by chromosome number); the correct
order is Smad8 (chromosome 3), Smad1 (chromosome 8), Amhr2 (chromosome
12), and Smad5 (chromosome 13). Mutant mice and their genotypes that were
analyzed in the manuscript are listed in Table 1. When possible, mice were
generated with three floxed alleles and one null allele (i.e., Smad1flox/
Smad5flox/flox and Smad1flox/flox Smad5flox/) for Smad1 and Smad5 to increase
the likelihood of complete recombination. However, Smad1/ Smad5/ and
Smad1flox/ Smad5flox/ mice cannot be generated, due to embryonic lethality
(1). Mice were genotyped from genomic tail DNA by use of PCR primers as
described previously (8, 53, 54; Huang et al., submitted) and by Southern blot
analysis (22). For analysis of recombination in granulosa cells, genomic DNA was
prepared by standard protocols from preovulatory stage granulosa cells as de-
scribed previously (38). Expression of cre from the Amhr2 locus in the ovary and
testis has been validated previously (24, 25). All experimental animals were
maintained in accordance with the NIH Guide for the Care and Use of Labo-
ratory Animals.
Fertility analysis. Fertility analysis was performed as described previously
(38). Mutant mice were compared to control littermates of the same genotype
that were negative for the cre allele. For example, Smad1flox/flox Smad5flox/flox
served as the controls for Smad1flox/flox Smad5flox/flox Amhr2cre/, etc. (Table 1).
Each mutant or control genotype was monitored over a 6-month period while
mated to known fertile wild-type (WT) mice. All breeding cages were set up
when the mice reached sexual maturity (6 weeks of age for females; 8 weeks of
age for males), and numbers of pups per litter were recorded. Mice were sacri-
ficed when they showed signs of infertility (missed three litters) or developed
visible tumors. Mice were monitored weekly for tumor development and were
sacrificed if they showed signs of distress.
Tissue collection. For necropsies, mice were anesthetized by isoflurane inha-
lation and then euthanized by cervical dislocation. Organs were dissected and
fixed in 10% neutral-buffered formalin for histology or stored in RNAlater
(Ambion) at 80°C until processed for RNA.
Histology and immunohistochemistry. Tissue embedding, sectioning, and
staining were performed by the Department of Pathology Core Facility (Baylor
College of Medicine) using standard techniques. Histological sections were cut at
4 to 6 m and stained with hematoxylin and eosin. Immunohistochemistry was
FIG. 1. Generation of single, double, and triple conditional knock-
outs. (A) Schematic representation depicting floxed and null alleles for
Smad1 (Smad1RobPC and Smad1Robcn, respectively) (53), floxed and
null alleles for Smad5 (Smad5fle2 and Smad5tm1Zuk, respectively) (8,
54), and a null allele for Smad8 (Huang et al., submitted). Only a
portion of each genomic locus is shown. In both Smad1 and Smad5,
loxP sites (open triangles) flank exon 2 (boxed), the first coding exon,
which when recombined produces a null allele. The Smad8 null allele
deletes exons 4 and 5, which encode the majority of the MH2 do-
main. PGK phosphoglycerate kinase promoter; hprt, hypoxanthine-
guanine phosphoribosyl transferase minigene. (B) Genotyping of sin-
gle, double, and triple control and conditional knockouts by PCR.
Each lane represents one mouse of eight possible genotypes. Repre-
sentative genotyping of genomic tail DNA is shown, with expected
sizes of PCR products as indicated. (C) Recombination of floxed (fl)
alleles in genomic DNA from isolated granulosa cells of cre-negative
(neg) and cre-positive (pos) Smad1flox/flox Smad5flox/flox 21-day-old
mice. When crossed to Amhr2cre/ mice, the deleted allele () is
detected in granulosa cells. Because four independent recombinations
have to occur in dKO (Smad1flox/flox Smad5flox/flox Amhr2cre/) mice,
granulosa cells isolated from young mice are mosaic for the deletions
and show variable levels of recombination between mice. Each lane
represents one mouse.
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performed as previously described (38), using formalin-fixed, paraffin-embedded
sections. Immunohistochemistry was performed using the Vectastain ABC
method (Vector Laboratories). Rabbit polyclonal anti-phospho-Smad2/3 (1:300;
Cell Signaling Technology) and rabbit polyclonal anti-inhibin  (1:500; a gift of
W. Vale, Salk Institute) antibodies were used. Troma-I (anti-cytokeratin 8)
(1:50) and Troma-III (anti-cytokeratin 19) (1:10) rat monoclonal antibodies were
obtained from the Developmental Studies Hybridoma Bank developed under the
auspices of the NICHD and maintained by the University of Iowa, Department
of Biological Sciences. Immunohistochemistry was performed on at least five
samples in duplicate. Immunoreactivity was visualized by diaminobenzidine tet-
rahydrochloride staining, and the tissue was counterstained in hematoxylin.
Granulosa cell cultures and ligand treatment. Collection and treatment of
WT granulosa cells were performed as previously described (36). CD1 female
mice 19 to 21 days old were injected intraperitoneally with 5 IU pregnant mare
serum gonadotropins (Calbiochem), and granulosa cells were collected 44 to 46 h
later by puncturing antral follicles, plated at a density of 5.5  105 cells/ml, and
treated immediately upon harvest in Dulbecco’s modified Eagle’s medium–F-12
medium supplemented with 0.5% heat-inactivated fetal bovine serum and 10
U/ml penicillin and streptomycin. Cells were treated for 5 h and then harvested
for RNA. BMP4 was a gift from Wyeth.
RNA analysis. RNA was extracted using a Qiagen RNeasy micro kit. cDNA
was prepared from 200 ng of total RNA by use of a SuperScript III first-strand
synthesis kit (Invitrogen) in a 50-l reaction. Real-time quantitative PCR
(qPCR) was performed as previously described (38) by using an Applied Bio-
systems (ABI) Prism 7500 sequence detection system, TaqMan master mix, and
predesigned gene expression assays. Data were analyzed by the CT method
(where CT is cycle threshold) using ABI 7500 system software (v1.2.3) as de-
scribed by ABI and normalized to the endogenous reference (Gapd). The mean
CT of the control samples was used as the calibrator sample. The averages and
standard errors of the means were calculated, and the relative amount of target
gene expression for each sample compared to the control was plotted in Excel
(Microsoft).
Microarray analysis. RNA was extracted by use of a Qiagen RNAeasy kit, and
RNA integrity, concentration, and quality were checked by the Baylor College of
Medicine Microarray Core Facility. Labeling, hybridization, washing, scanning, and
initial analysis were performed by the Baylor College of Medicine Microarray Core
Facility using standard Affymetrix protocols and an Affymetrix mouse genome 430
2.0 array. Six chips were analyzed from three independent pools of WT granulosa
cell samples (each pool was collected from two to three females) and three inde-
pendent tumor samples (two samples of Smad1flox/flox Smad5flox/flox Smad8/
Amhr2cre/ and one sample of Smad1flox/flox Smad5flox/flox Smad8/ Amhr2cre/).
Affymetrix CEL files were imported into GeneSpring GX (Agilent), and GC robust
multiarray average was used to perform background correction and normalization.
Differential gene expression was filtered using the volcano plot filter in GeneSpring,
with a P value of 0.001 and a minimum twofold change. Forty-three genes would
have been expected to change by chance alone. Probe sets that were considered to
be “absent” in four of six samples or that had a signal intensity of less than 150 under
both conditions, as determined by Affymetrix GCOS software, were removed from
the gene lists. This resulted in 354 differentially expressed probe sets, which, by
taking into account multiple probe sets for the same gene, corresponded to 153
genes upregulated at least twofold and 171 genes downregulated at least twofold.
Gene lists were imported into DAVID bioinformatic software (http://david.abcc
.ncifcrf.gov/home.jsp) for KEGG pathway analysis (12).
GSEA. Gene set enrichment analysis (GSEA) (52) was performed using
GSEA-P v2 with the default parameters (http://www.broad.mit.edu/gsea/), except
that the median intensity of probes corresponding to the same gene was used to
collapse probe sets. Gene sets were exported from database C2 of MSigDB v2.1
(http://www.broad.mit.edu/gsea/msigdb/index.jsp) (52), and only canonical path-
ways from BioCarta, Gene Ontology, GenMAPP (www.genmapp.org), Signaling
Transduction KE, Signaling Alliance, and Sigma Aldrich were used. Of the 456
canonical gene sets, only 337 passed the selection criteria of a minimum size of
10 and maximum size of 500. This resulted in one gene set that was enriched in
WT compared to tumor cells and one gene set enriched in tumor cells compared
to WT cells by use of a false discovery rate (q  0.25, as recommended).
Statistical analysis. Statistical analysis was performed with JMP v5.1 (SAS
Institute, Inc.) or MATLAB (Mathworks) statistical packages. Fertility data were
tested using the Kruskal-Wallis analysis of ranks test for multiple comparisons
and Tukey’s least significant difference test for post hoc multiple comparisons to
identify statistically different groups. Parametric data (qPCR data) were analyzed
by Student’s t test (for single comparisons) or one-way analysis of variance (for
multiple comparisons) followed by a Tukey-Kramer honestly significant differ-
ence post hoc test. Parametric data are shown as means, with standard errors of
the means as error bars. Statistical significance was set at  	 0.05. A minimum
of three independent experiments was used for statistical comparisons.
Nucleotide sequence accession number. The microarray data set has been
deposited at NIH Gene Expression Omnibus under the series accession number
GSE8156 (http://www.ncbi.nlm.nih.gov/projects/geo).
RESULTS
Absence of Smad1, Smad5, or Smad8 in somatic cells of the
gonads does not affect fertility. We generated single, gonad-
specific knockouts of Smad1 and Smad5 by crossing Smad1flox/flox
or Smad5flox/flox mice to mice heterozygous for each respective
null allele (Smad1/ or Smad5/) (8, 53, 54) (Fig. 1 and Table
1) that also expressed cre recombinase from the anti-Mu¨llerian
hormone receptor type II (Amhr2) locus (22). Amhr2cre/ mice
express cre recombinase predominantly in granulosa cells of de-
veloping ovarian follicles (4, 25, 38) and Sertoli and Leydig cells of
the testis in males (24). To control for potential genetic back-
ground effects, comparisons were made between siblings of the
same genotype, except for the presence or absence of cre (e.g.,
between Smad1flox/ and Smad1flox/ Amhr2cre/ littermates), as
well as between lines (e.g., between Smad1flox/ Amhr2cre/ and
Smad5flox/ Amhr2cre/ mice) (Fig. 2; Table 1). Heterozygous
mice (Smad1/ or Smad5/), Smad8/ mice, and Smad1 or
TABLE 1. List of mutant mouse lines analyzed for Smad1, Smad5, and Smad8
Designation Genotype Control strain Fertilitydefecta
Tumor
developmentb
Smad1 cKO Smad1flox/ Amhr2cre/ Smad1flox/ No No
Smad5 cKO Smad5flox/ Amhr2cre/ Smad5flox/ No No
Smad8 null Smad8/ WT or Smad8/ No No
Smad5 Smad8 dKO Smad5flox/ Smad8/ Amhr2cre/ Smad5/ Smad8/ No No
Smad1 Smad5 dKO Smad1flox/ Smad5flox/flox Amhr2cre/ Smad1flox/ Smad5flox/flox Yes Yes
Smad1flox/flox Smad5flox/ Amhr2cre/ Smad1flox/flox Smad5flox/ Yes Yes
Smad1flox/flox Smad5flox/flox Amhr2cre/ Smad1flox/flox Smad5flox/flox Yes Yes
Smad1 Smad5 Smad8 tKO Smad1flox/ Smad5flox/flox Smad8/ Amhr2cre/ Smad1flox/ Smad5flox/flox Smad8/ Yes Yes
Smad1flox/flox Smad5flox/ Smad8/ Amhr2cre/ Smad1flox/flox Smad5flox/ Smad8/ Yes Yes
Smad1flox/flox Smad5flox/flox Smad8/ Amhr2cre/ Smad1flox/flox Smad5flox/flox Smad8/ Yes Yes
a Fertility defect of the mutant strain is given for female mice.
b Gonadal tumor development is indicated for both male and female mutant mice.
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Smad5 conditional knockout (Smad1 cKO or Smad5 cKO) mice
were viable and fertile (Fig. 2A and Table 1).
Female Smad1 Smad5 dKO and Smad1 Smad5 Smad8 tKO
mice develop fertility defects and metastatic granulosa cell
tumors. To test for redundancy between the different BR-
SMADs, we generated Smad1 Smad5 dKO mice, Smad5
Smad8 dKO mice, and a Smad1 Smad5 Smad8 triple condi-
tional knockout (tKO) mouse. Smad5 Smad8 dKO mice were
viable and fertile (Fig. 2). In contrast, Smad1 Smad5 dKO and
Smad1 Smad5 Smad8 tKO female mice became infertile after
3 to 4 months of breeding (Fig. 2B). Four out of 10 Smad1
Smad5 dKO female mice in our initial breeding study died
before 24 weeks, while all of the control mice were viable.
Upon necropsy, Smad1 Smad5 dKO and Smad1 Smad5 Smad8
tKO females demonstrated unilateral or bilateral ovarian tu-
mors (Fig. 3). Before 8 weeks, the ovaries, uteri, and oviducts
were grossly normal. After 3 months, 100% of the Smad1
Smad5 dKO (15/15) and Smad1 Smad5 Smad8 tKO (15/15)
female mice showed evidence of tumors. Histological analysis
revealed that the tumors were poorly differentiated granulosa
cell tumors, which were positive for inhibin  (Fig. 3) and
FIG. 2. Fertility analysis of Smad1, Smad5, and Smad8 female cKO
mice. (A) Adult female mice of the indicated genotypes (cre negative []
and cre positive []) at 6 weeks of age were bred to WT males, and the
numbers of pups were recorded for 6 months. Data are shown as median
pups per litter, with the upper and lower edges of the boxes equal to the
25% and 75% quartiles and whiskers the 5% and 95% quartiles. Mice
with single conditional knockouts for Smad1 (cre negative, n 	 5; cre
positive, n 	 6) or Smad5 (cre negative, n 	 10; cre positive, n 	 4) or
dKO for Smad5 Smad8 (controls are Smad5/ Smad8/, n 	 4, com-
pared to Smad5flox/ Smad8/ Amhr2cre/, n 	 3) have litter sizes and
reproductive life spans similar to those for their control littermates. Fe-
male Smad1 Smad5 dKO (cre positive, n	 6) and Smad1 Smad5 Smad8
tKO (cre positive, n	 6) mice are significantly different from their control
littermates (P  0.001) (cre negative, n 	 5 and n 	 6 for dKO and tKO
mice, respectively). There is no statistical difference between the numbers
of Smad1 Smad5 dKO and Smad1 Smad5 Smad8 tKO median pups/litter,
indicating that loss of Smad8 has no additional effect on fertility. Letters
written above the median line for each group indicate statistical signifi-
cance by Kruskal-Wallis analysis of ranks test, followed by Tukey’s post
hoc test. Boxes not connected by the same letter are statistically different;
for example, “A” is statistically different from “E” but not “A,B.” (B) Fe-
male Smad1 Smad5 dKO and Smad1 Smad5 Smad8 tKO mice become
infertile with age. Total accumulated pups were counted from five breed-
ing pairs for each genotype over 6 months. The dKO and tKO mice are
similar in their breeding profiles. Infertility was evident in dKO and tKO
mice after 3 to 4 months of breeding.
FIG. 3. Tumor development in Smad1 Smad5 and Smad1 Smad5
Smad8 female cKO mice. (A) Reproductive tract from an infertile
5.5-month-old Smad1flox/flox Smad5flox/ Amhr2cre/ dKO mouse. The
left ovary (ov) and oviduct (ovi) and both uterine (ut) horns have
normal morphology. A large tumor is seen on the right. Bar, 1 cm.
(B) Bilateral tumor development in an infertile 8-month-old
Smad1flox/flox Smad5flox/ Smad8/ Amhr2cre/ dKO female mouse.
Bar, 1 cm. (C) Ovary from a 32-week-old Smad1flox/flox Smad5flox/flox
Smad8/ Amhr2cre/ tKO mouse. Most of the ovary is replaced by
tumor cells, with few remaining follicles. A higher magnification is
shown as panel D, demonstrating tumor (tu) cells and a single second-
ary follicle (sf). Bar, 100 m. (E) Inhibin  immunoreactivity in an
ovary from a 17-week-old control (Smad1flox/flox Smad5flox/flox
Smad8/) mouse. Positive staining (brown) is limited predominantly
to follicular granulosa cells, and the oviduct is negative. af, antral
follicle; bu, ovarian bursa. Bar, 50 m. (F) Ovary from a 17-week-old
tKO (Smad1flox/flox Smad5flox/flox Smad8/ Amhr2cre/) mouse shows
extensive inhibin  immunoreactivity in the granulosa cells, ovarian
stroma, tumor tissue from the ovary (tu), and small patches in the
oviduct (arrowheads), which likely represent growth of the tumor from
the ovary into the oviduct. gr, granulosa cells. Bar, 50 m.
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negative for cytokeratins (data not shown). Aging Smad1
Smad5 dKO and Smad1 Smad5 Smad8 tKO mice also demon-
strated peritoneal metastases (Fig. 4 and Table 2) that were
histologically identical to the primary granulosa cell tumor,
with strong inhibin  immunoreactivity (Fig. 4E). Tumors
spread to the lymph nodes, and 6 of 12 knockout females 
9
months old developed hemorrhagic ascites. Smad1 and Smad5
recombined alleles were detected exclusively in the metastases,
demonstrating that extraovarian tumors derived from null cells
(Fig. 4F). No tumors were found in control mice or in 1-year-
old Smad1 Smad5 dKO ovariectomized female mice (n 	 8).
Female Smad1 Smad5 dKO and Smad1 Smad5 Smad8 tKO
mice had similar fertility defects and tumor developments,
supporting studies with mouse embryos that demonstrate a
strong genetic interaction between Smad1 and Smad5 but not
with Smad8/ mice (1). Therefore, subsequent studies were
carried out with only Smad1 Smad5 dKO mice.
Male Smad1 Smad5 dKO mice are fertile but develop met-
astatic Sertoli-Leydig tumors. Male Smad1 Smad5 dKO mice
were fertile and, when bred to WT females, produced litters
that were similar in size to those from control males (8.6  0.7
[n 	 8] versus 8.9  0.9 [n 	 4], respectively). Signs of a mild
fertility defect, detected as irregularly spaced litters in 3/8
breeding pairs, appeared after 3 months of age, but this defect
resulted in only a 16% decrease in litters per month (0.76 
0.45 litters per month for Smad1 Smad5 dKO mice, compared
to an average of 0.9  2.3 typically obtained in the mixed
hybrid background of our mouse colonies). Thus, unlike results
for female Smad1 Smad5 dKO mice, the overall ability of male
mice to produce normal-sized litters was not disrupted (i.e.,
they were not initially subfertile). However, three males in the
Smad1 Smad5 breeding pairs died of unknown causes before 6
months of age, and two of these had bilateral testicular tumors.
After 28 weeks of age, all male Smad1 Smad5 dKO mice
(14/14) showed gross tumor development in the testes. Tumor
development occurred mostly focally (Fig. 5B and C), invading
the tunica albuginea and implanting outside the testis. Less
commonly, tumor cells were isolated within seminiferous tu-
bules (data not shown). None of the control male mice devel-
oped tumors. Early-stage tumors from Smad1 Smad5 dKO
males appeared to be sex cord stromal tumors with Sertoli and
Leydig cell differentiation (Fig. 5C and D).
In addition, with age, male Smad1 Smad5 dKO mice devel-
oped distended abdomens that contained hemorrhagic ascites
(Fig. 5E and F). All of the male mice with ascites showed
extensive testis tumor development in addition to lymphatic
and peritoneal metastases. Sertoli-Leydig cell tumors from
male Smad1 Smad5 dKO mice contained patchy inhibin im-
munoreactivity (Fig. 5D) and were negative for cytokeratins 8
and 19 (data not shown). Therefore, similarly to results for
females, loss of Smad1 Smad5 in gonadal somatic cells resulted
in 100% penetrance and metastases. The higher frequency of
ascites development in males also suggests that the modes of
TABLE 2. Locations of visible metastases in Smad1 Smad5 dKO
and Smad1 Smad5 Smad8 tKO female mice
Tissue(s) No. of mice showingmetastasisa
Diaphragm .................................................................................. 4
Liver............................................................................................. 3
Mesentery, intestine................................................................... 3
Pancreas ...................................................................................... 3
Spleen .......................................................................................... 3
Lymph nodes .............................................................................. 3
Unknown peritoneal .................................................................. 2
Stomach (fascia)......................................................................... 2
Uterus (serosa)........................................................................... 2
Kidney.......................................................................................... 1
Small intestine ............................................................................ 1
Total.............................................................................................13
a The number of mice with visible metastases in each organ is shown, of 13
mice examined (“Total”) (7 Smad1 Smad5 dKO mice and 6 Smad1 Smad5
Smad8 tKO mice) demonstrating metastatic tumor growth. Typically, in mice
with metastases, more than one organ in each mouse is involved.
FIG. 4. Intraperitoneal metastases in female cKO mice. (A) The
percentage of knockout female mice with visible metastases in the
peritoneum increases with age. The number of mice in each group is as
follows: 0 to 12 weeks, n 	 11; 13 to 24 weeks, n 	 9; 25 to 36 weeks,
n 	 15; and 37 to 50 weeks, n 	 4. Data are from both dKO and tKO
mice. (B) Three metastases to the diaphragm of an 8-month-old
Smad1 Smad5 Smad8 tKO female. Bar, 5 mm. The larger growth was
dissected and is shown by hematoxylin and eosin histology in panel D.
Bar in panel D, 80 m. (C) Metastases (arrows) to the spleen in an
8-month-old Smad1flox/flox Smad5flox/flox Smad8/ Amhr2cre/ dKO fe-
male. Bar, 5 mm. (E) Eight-month-old Smad1 Smad5 Smad8 tKO
mouse with a metastatic lesion invading the liver. The tumor shows
strong inhibin -positive staining (brown staining, indicated by ar-
rows), while the liver is negative. Bar, 200 m. (F) PCR analysis of
Smad1 and Smad5 alleles in genomic DNA from isolated metastases
shows complete recombination () of the floxed alleles. Two different
mice are represented, and genomic tail DNA (tail) is shown as unre-
combined floxed allele controls. dia, diaphragm; om, omentum.
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metastasis differ between the sexes (i.e., primarily lymphatic
spread in males versus peritoneal spread in females).
Gene expression changes in Smad1 Smad5 dKO mice. To
determine gene expression changes in the tumors, we performed
microarray and qPCR analyses on dissected Smad1 Smad5 and
Smad1 Smad5 Smad8 mutant granulosa cell tumors and com-
pared these to isolated WT granulosa cells. Microarrays were
performed with females because granulosa cells, unlike Sertoli
cells, are readily collectable in sufficient quantities without cultur-
ing and can be used for comparison. Microarray analysis identi-
fied 171 genes significantly downregulated (P 0.001) twofold or
more, while 153 genes were significantly upregulated (P 0.001)
twofold or more (see Tables S1 and S2 in the supplemental
material). Microarray results were analyzed by GSEA (52) to
identify functional gene sets that are altered in tumor cells. Of the
337 gene sets examined, one set, which was associated with ovar-
ian infertility, was significantly underrepresented in BR-SMAD
knockout tumor cells compared with WT cells (false discovery
rate q value of 0.25) (see Table S3 in the supplemental mate-
rial). In addition, one gene set representing extracellular matrix
pathway genes was overrepresented in BR-SMAD knockout tu-
mor cells compared to WT cells (q  0.25) (see Table S4 in the
supplemental material).
By KEGG pathway analysis, only the TGF family signaling
pathway was significantly overrepresented (P 	 0.02) in the dif-
ferentially expressed gene lists. This list included genes encoding
ligands (Bmp7 and inhibin B [Inhbb]), receptors (BMP recep-
tors type II [Bmpr2] and type IB [Bmpr1b]), negative regulatory
proteins (gremlin [Grem1]), and potential downstream target
genes (cartilage oligomeric protein [Comp] and inhibitor of dif-
ferentiation-1 [Id1]). Of the downregulated genes, five of six
genes (Comp, Grem1, Inhbb, Bmpr2, and Id1) were reconfirmed
by qPCR (Fig. 6A). Grem1 is a known target of BMP signaling in
granulosa cells (36), but few other gene targets are known for this
cell type. To determine which genes are regulated by BMPs in
granulosa cells and thus those genes that may be directly affected
by loss of SMAD1/5 in Smad1 Smad5 dKO tumors, primary
cultures of WT granulosa cells were treated with recombinant
BMP4. Only Id1 and Grem1 were upregulated within 5 h of
treatment (Fig. 6B). Comp, Inhbb, or Bmpr2 gene expression did
not change (Fig. 6B). This suggests that Comp, Inhbb, and Bmpr2
are altered in Smad1 Smad5 dKO tumors as an indirect conse-
quence of loss of BR-SMAD signaling.
In many human cancers, TGF stimulates invasion and metas-
tasis. Canonical signaling by TGF results in phosphorylation and
nuclear accumulation of SMAD2 and SMAD3. By immunohis-
tochemistry, all Smad1 Smad5 dKO granulosa cell tumors and
metastases contained high levels of phospho-SMAD2/3 immuno-
reactivity in cell nuclei (Fig. 6D and E). Phospho-SMAD2/3 was
also detected in all male Smad1 Smad5 dKO tumors (n	 6) (data
not shown). The nuclear phospho-SMAD2/3 immunoreactivity in
Smad1 Smad5 dKO tumors supports a hypothesis that TGF
and/or activin is functional in these tumors. Because the activin
antagonist inhibin is highly expressed in Smad1 Smad5 dKO tu-
mors and metastases (Fig. 3E and F and 4E), it is unlikely that
dimeric activin is either produced or able to signal; therefore,
phospho-SMAD2/3 is likely attributable to TGF activity. More-
over, Smad1 Smad5 dKO and Smad1 Smad5 Smad8 tKO tumors
express TGF1, TGF3, and the TGF type I receptor (Tgfbr1,
or Alk5), type II receptor (Tgfbr2), and type III receptors (data
not shown). An examination of the list of genes significantly
upregulated in female Smad1 Smad5 tumors (see Table S2 in the
supplemental material) provided further evidence for activation
of the TGF/SMAD2/3 pathway. At least eight genes with at least
one literature citation identifying the gene as a downstream target
of TGF or SMAD2/3 were identified. This list includes Hmga2,
Mmp2, and Tgfbi, and expression changes in these genes in Smad1
Smad5 tumors were verified by qPCR (Fig. 6C). Taken together,
these data indicate that TGF signaling is active in Smad1 Smad5
dKO tumor cells when the Smad1 Smad5 pathway is disrupted in
vivo and suggest a potential role for the BR-SMAD pathway in
modulating TGF function.
FIG. 5. Gross morphology and histology of testicular tumors in
male Smad1 Smad5 dKO mice. (A) Normal testis morphology in a
3-month-old Smad1 Smad5 dKO male. Before 12 weeks of age, only
50% of mutant males have visible tumors. epi, head of epididymis; tail,
tail of epididymis; te, testis; vd, vas deferens. Bar, 2 mm. (B) Tumor
development in a 14-week-old Smad1 Smad5 dKO male. The tumor is
located at one pole of the testis and extends outward, implanting on
the capsule. Bar, 2 mm. (C) Hematoxylin and eosin-stained cross-
section of lobular tumor in the testis shown in panel B. Bar, 1 mm.
(D) Inhibin (Inh)  immunoreactivity (brown staining, arrows) is fo-
cally positive in a tumor from an 11-week-old Smad1 Smad5 dKO
male. Bar, 20 m. (E) Hemorrhagic ascites formation in a 42-week-old
Smad1 Smad5 dKO male compared to a control male of the same age.
(F) The percentage of male Smad1 Smad5 dKO mice that develop
hemorrhagic ascites increases with age.
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DISCUSSION
Our results uncover a profound role for the BMP pathway in
vivo for regulating tumorigenesis in somatic gonadal cells. In vivo
evidence, including genetic models, for a tumor suppressor role
for the BR-SMAD pathway has been lacking, except for the BMP
type I receptor BMPR1A. However, many in vitro cell culture
studies have suggested a role for the BMP family in regulating
cellular differentiation and growth control. During our experi-
ments to analyze the in vivo reproductive role of the BR-SMADs
in ovarian somatic cells, we discovered that along with fertility
defects, 100% of the female mice conditionally null for Smad1
Smad5 or Smad1 Smad5 Smad8 develop granulosa cell tumors. In
BR-SMAD knockout males, tumors develop more slowly but also
are 100% penetrant. Additionally, both male and female cKO
mice demonstrate a high degree of metastases. There are few
signaling pathway mutations associated with human sex cord stro-
mal tumor development (i.e., granulosa, Sertoli and Leydig tu-
mors), and based on the highly penetrant metastatic tumor phe-
notype of the Smad1 Smad5 dKO and Smad1 Smad5 Smad8 tKO
mice, the BR-SMAD pathway and the genes that it regulates
become important candidate pathways for further disease re-
search for these and other cancers.
FIG. 6. Gene expression changes and TGF activity in tumors from female Smad1 Smad5 dKO mice. (A) qPCR verification of genes expressed
in Smad1 Smad5 dKO tumors compared to control granulosa cells (Smad1flox/flox Smad5flox/flox) for genes significantly downregulated in tumors in
the microarray analysis. Four independent samples were used for each group. Values are means  standard errors of the means, relative to values
for the control group. Asterisks (*, P 0.05; **, P 0.01) indicate statistical significance by two-tailed t test. ns, not significant. (B) qPCR analysis
of gene expression in 5-h control-treated and BMP4-treated (100 ng/ml) WT granulosa cells from four independent experiments indicates a
significant upregulation of Grem1 and Id1 by BMP4. Asterisks denote statistical significance (**, P 0.01) by two-tailed Student’s t test. (C) qPCR
verification of Bmp7, Hmga2, Mmp2, and Tgfbi expression in control granulosa cells compared to granulosa cell tumors of Smad1 Smad5 dKO mice,
showing that all are significantly upregulated (P  0.05) in tumors by one-way analysis of variance and Tukey-Kramer honestly significant
difference. (D and E) Immunohistochemistry for phospho-SMAD2/3 in (D) a granulosa cell tumor from a 7-month-old Smad1 Smad5 Smad8 tKO
female and (E) a tumor within a lymph node (lym) from an 8-month-old Smad1flox/flox Smad5flox/flox Smad8/ Amhr2cre/ dKO female. Positive
immunoreactivity (brown staining) is seen in tumor nuclei (arrow, follicle-like structure within the tumor). The epithelium of the oviduct (ovi) is
normally positive. Bar, 50 m. (F) Hypothetical model for tumor development through loss of SMAD signaling in the gonad. Smad1 Smad5 dKO
mice develop sex cord stromal tumors, as do inhibin  knockout mice (31). Loss of SMAD1/5 signaling suggests that the BMP pathway has a tumor
suppressor function in the gonad. Interactions between the BMP and the activin/TGF pathways to control growth and differentiation of granulosa
cells could occur at many different levels (dashed arrow) and remain to be determined.
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Even though the BMP type I receptors have been shown to
phosphorylate SMAD1, SMAD5, or SMAD8, the degree of
redundancy between these SMADs is unknown. Smad8 null
mice are viable and fertile (1), while Smad1 and Smad5 ho-
mozygous and heterozygous null embryos die at midgestation
(8, 53). Several conditional alleles of Smad1 and Smad5 have
been generated to circumvent the lethality and allow for the
analysis of BR-SMADs in later-stage embryonic and adult
tissues (1, 21, 54). However, few adult tissue-specific knockout
mice have yet to be reported. Recently, it was shown that
conditional deletion of Smad5 in adult hematopoietic stem cell
lineages has no effect on adult hematopoiesis, and this was
attributed to potential functional compensation by SMAD1,
which is equivalently expressed in WT and Smad5 null hema-
topoietic stem cell lineages (49). Similarly, none of our single
conditional knockouts for Smad1 or Smad5 or a knockout of
Smad8 demonstrates significant fertility defects for the param-
eters that we tested. It was only through combined loss of
Smad1 and Smad5 that we demonstrated the metastatic tumor
phenotype in mouse gonadal cells. These data support studies
with mouse embryos that indicate a strong genetic interaction
between Smad1 and Smad5 (1). Thus, our data on Smad1
Smad5 dKO mice demonstrate that there is significant func-
tional redundancy between SMAD1 and SMAD5. Therefore,
genetic models for the BR-SMAD pathway in other cell and
tissue types will likely have to take this into account and re-
quire modification of both of these genes to fully uncover the
function of the BR-SMAD pathway.
While our studies demonstrate redundancy between SMAD1
and SMAD5, our data do not support additional redundancy with
SMAD8, even though Smad8 is coexpressed with Smad1 and
Smad5 in granulosa cells (data not shown). At the amino acid
level, SMAD1 and SMAD5 are more similar to each other
than to SMAD8, and this divergence of SMAD1/5 and
SMAD8 occurred early during vertebrate evolution (1). Stud-
ies of genetic mutations in mouse embryos support the hypoth-
esis that SMAD8 is not redundant with SMAD1 and SMAD5
because deletion of Smad8 has no effect on the phenotype of
Smad1 or Smad5 null embryos and removal of one copy of
Smad1 or Smad5 has no effect on the Smad8 null phenotype
(1). In our studies described here, no fertility or tumor phe-
notype was seen in Smad8 null female mice or Smad5 Smad8
dKO mice. Furthermore, there was no additional effect of
Smad8 loss in female fertility or tumor formation when Smad1
Smad5 dKO and Smad1 Smad5 Smad8 tKO mice were com-
pared. The lack of genetic interaction between the SMAD1/5
and SMAD8 pathways may indicate that SMAD8 functions in
another non-BMP pathway in the ovary, such as for anti-Mu¨l-
lerian hormone/Mu¨llerian-inhibiting substance, which has re-
cently been shown to use different BR-SMADs sequentially
during Mu¨llerian duct regression (57). Alternatively, SMAD8,
but not SMAD1/5, may interact with a SMAD-interacting pro-
tein, and loss of this interaction through loss of Smad8 is not
critical during the development of the tumorigenesis pheno-
type.
In many human cancers, TGF is overexpressed and stim-
ulates tumor invasion and metastasis. The SMAD2/3 pathway
is consistently activated in tumors and metastases of both male
and female Smad1 Smad5 dKO and Smad1 Smad5 Smad8 tKO
mice, as indicated by nuclear phospho-SMAD2/3 immunohis-
tochemistry. It is unclear what the contribution of TGF ac-
tivity is to tumor development in granulosa cells. We analyzed
several candidate genes that are known to be directly down-
stream of TGF signaling and implicated in tumor develop-
ment and metastasis. We found that several of these genes,
including Hmga2, Mmp2, and Tgfbi, are significantly upregu-
lated. Upregulation of Mmp2 expression has been linked to
metastatic potential in some cancers (32). Overexpression of
Tgfbi and Hmga2 has been demonstrated in a number of hu-
man cancers (6, 46, 47), and mouse models have shown that
Hmga2 overexpression is sufficient to induce mesenchymal tu-
mor development (55). How the suite of genes expressed in
Smad1 Smad5 dKO sex cord stromal tumors contribute to
malignant transformation remains to be determined.
In some cell types (e.g., endothelial cells), TGF also signals
through SMAD1/5 when the type I receptor activin receptor-
like kinase 1 (Acvrl1, also called Alk1) is expressed (17). There-
fore, an additional possibility is that loss of TGF signaling
through SMAD1/5 in the Smad1 Smad5 dKO mouse triggers
the tumor phenotype. However, this does not appear to be a
likely explanation for tumor development in the Smad1 Smad5
and Smad1 Smad5 Smad8 cKO mice, because Alk1 is not
expressed in granulosa cells and we did not detect phosphory-
lation of SMAD1 or SMAD5 in TGF-treated WT granulosa
cells by immunoanalysis (data not shown). In addition, a recent
study has demonstrated that ALK1 activates BR-SMADS in
endothelial cells after binding BMP9 and BMP10, and thus
these ligands, and not TGF, may represent the physiological
ligands for this receptor (11).
It is unknown whether activation of the TGF pathway in
the Smad1 Smad5 dKO and Smad1 Smad5 Smad8 tKO tumors
is a primary event caused by loss of SMAD1/5 or occurs sec-
ondarily during gonadal tumor development. However, it has
been shown in some cell types that the BR-SMAD pathway
directly counteracts TGF activity through opposing regula-
tion of the same gene promoter by SMAD1/5 and SMAD2/3.
For instance, BMP7 reverses the TGF1-induced epithelial-
mesenchymal transition through a SMAD-dependent pathway
in renal distal tubular and mammary ductal epithelial cells in
part by antagonistic regulation of the E-cadherin promoter:
TGF signaling through SMAD3 downregulates transcription
through the E-cadherin promoter, while BMP7 signaling
through SMAD5 upregulates it (56). BMP7 restores E-cad-
herin expression to normal values even when both the
SMAD2/3 and SMAD1/5 pathways are activated concurrently,
suggesting that the BR-SMAD pathway can override the AR-
SMAD pathway. While E-cadherin is not expressed in granu-
losa cells or Smad1 Smad5 dKO tumors, a similar mechanism
of SMAD promoter antagonism on granulosa cell target genes
may operate in granulosa cells during folliculogenesis. Approx-
imately 25 other genes have been shown to be coregulated by
the two SMAD pathways in epithelial cells, including the Id
genes (26). However, few direct downstream target genes of
BMP or TGF have been reported for granulosa cells. In this
study, we found that BMP4 regulates Id1 in WT granulosa cells
and that, furthermore, the expression of Id1 is downregulated
significantly in Smad1 Smad5 tumor cells, although the func-
tional consequence of this is not known. The identification of
additional Smad1 Smad5 target genes during folliculogenesis
and granulosa cell differentiation will be critical for under-
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standing tumor development in the Smad1 Smad5 dKO mouse
model.
Death in most cancer patients is primarily the result of
metastatic disease (51), and granulosa cell tumors metastasize
in an estimated 5 to 25% of cases. Different types of ovarian
cancer (i.e., epithelial and sex cord stromal cancers) have sim-
ilar sites of metastasis (45) and frequently spread directly into
the peritoneal cavity by growth onto adjacent organs, seeding
of tumor cells present in peritoneal fluid, and dissemination via
the lymphatic system (35). Very few mouse knockouts develop
metastatic tumors, and among mouse models of granulosa cell
tumors, the Smad1 Smad5 dKO model is unique because pre-
vious models (4, 31, 43) do not demonstrate tumor spread
outside the gonad. The pattern of peritoneal spread of the
female Smad1 Smad5 dKO tumors closely mimics the human
dissemination pattern, and both male and female Smad1
Smad5 dKO mouse models demonstrate evidence of tumor
spread through the lymphatic system. Thus, the Smad1 Smad5
dKO mouse model is an important step in uncovering novel
redundant roles of SMAD1 and SMAD5 in controlling tumor
cell migration to distant sites.
However, there are phenotypic dissimilarities of Smad1
Smad5 dKO mice to other mouse models of granulosa tumors,
which suggest functional differences. Smad1 Smad5 dKO gran-
ulosa cell tumors lack tubule-like structures that typify inhibin
 (Inha) null sex cord stromal tumors (31) and also do not
develop the cancer cachexia-like wasting syndrome seen in
Inha knockout mice. Granulosa cell tumors also develop in
female mice engineered to express a stable form of -catenin
(4). We examined -catenin immunoreactivity in mouse
Smad1 Smad5 dKO tumors, but in the majority of Smad1
Smad5 dKO tumor cells, -catenin is not nuclear but mem-
brane bound (data not shown). In contrast to Smad1 Smad5
dKO females, -catenin females show a low penetrance (57%
in females by 7.5 months, versus 100% penetrance at 3 months
in Smad1 Smad5 dKO female mice) and do not develop me-
tastases (4) and males do not develop tumors (D. Boerboom,
personal communication). Additional studies will be necessary
to understand the pathologies leading to tumor development
in these mouse models and the ways they can contribute to our
understanding of sex cord stromal cell tumor formation.
Additional genetic mouse models have defined the roles of
TGF family ligands or SMAD proteins in granulosa cell phys-
iology and provide a foundation for understanding the role for
the TGF family in granulosa cell tumor development (Fig.
6F). The data in this study demonstrate that when the BR-
SMADs are deleted, tumors develop. When loss-of-function
mutations in the activin/TGF pathway are made, inappropri-
ate granulosa cell differentiation occurs and no tumors develop
(37, 38). Activin gain of function (via deletion of the inhibin 
subunit leading to activin overexpression) results in gonadal
sex cord stromal tumors, mediated in part by the AR-SMAD
SMAD3 (27, 28, 31). Combined, these phenotypes suggest a
possible interplay between the BR-SMAD and AR-SMAD
signaling pathways, which when unbalanced may lead to tumor
development (Fig. 6F).
It is unknown if tumor suppression by SMAD1 and SMAD5
is a mechanism found in nongonadal cell types. No germ line
mutations have been identified in the limited numbers of stud-
ies of humans that examined BR-SMADs (3, 16). However, if
BR-SMADS are as redundant in humans, as we and others (1)
suspect, then a combination of loss of function in both SMAD1
and SMAD5 would be required for developing human cancers,
and this may be an unlikely event. However, because haploin-
sufficiency in many transcription factors causes human dis-
eases, a significant distortion in SMAD1 SMAD5 gene expres-
sion or activity in humans may have the same phenotypic effect
as the Smad1 Smad5 double null mutation and result in tu-
morigenesis. Thus, there are many possible scenarios that
would result in downregulated SMAD1 SMAD5 expression or
activity, including mutations in common upstream SMAD1
SMAD5 regulatory pathways, mutations in a SMAD1/5-inter-
acting protein, or mutations in a common downstream target
gene. Evidence for downregulation in human cancers includes
loss of SMAD1 expression in cervical carcinomas (48) and loss
of SMAD8 in breast, colon, and prostate cancer (9, 19). An
important consideration for future cancer research will be to
determine whether loss of Smad1 Smad5 Smad8 and their
downstream targets in gonadal and nongonadal cells also re-
sults in tumor formation and metastatic disease in humans.
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